GentiBio
GentiBio, Inc.: Pioneering biotherapeutics with engineered T cells to treat immune and allergic diseases.
Founded
2020GentiBio, Inc.: Pioneering biotherapeutics with engineered T cells to treat immune and allergic diseases.
GentiBio, Inc. is an early-stage biotherapeutics company founded by experts in Treg biology and synthetic immunology. The company’s core mission is to develop engineered regulatory T cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. Utilizing a modular engineering platform, GentiBio creates potent, stable, and targeted Treg phenotypes tailored to specific diseases. Their market focus includes addressing the key challenges in Treg therapeutics by producing scalable and patient-specific treatments.
Notable affiliated individuals include the co-founders who are pioneers in their respective fields of Treg biology and synthetic immunology. GentiBio has attracted significant attention and investment from leading biotech investors. Key achievements include the development of a proprietary platform that simplifies manufacturing and allows for patient-specific dose titration. The company’s innovative approach has the potential to make a significant impact on the treatment of various immune-related diseases, positioning it as a leader in the biotherapeutics space.
Companies similar to GentiBio include Geneius, Sonoma Biotherapeutics, Cell BioEngines and TRex Bio.
GentiBio was founded in 2020.
GentiBio's headquarters is located in Cambridge, MA, US.
GentiBio's most recent funding round was for $157M (USD) in August 2021.
As of Aug 11, 2021, GentiBio has raised a total of $177M (USD).
GentiBio has 176 employees as of Feb 4, 2024.
Cell BioEngines
cellbioengines.com
